Literature DB >> 17237388

The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Ral.

David J J de Gorter1, Johanna C M Vos, Steven T Pals, Marcel Spaargaren.   

Abstract

Signaling by the BCR involves activation of several members of the Ras superfamily of small GTPases, among which is Ras itself. Ras can control the activity of multiple effectors, including Raf, PI3K, and guanine nucleotide exchange factors for the small GTPase Ral. Ras, Raf, and PI3K have been implicated in a variety of processes underlying B cell development, differentiation, and function; however, the role of Ral in B lymphocytes remains to be established. In this study, we show that Ral is activated upon BCR stimulation in human tonsillar and mouse splenic B lymphocytes and in B cell lines. Using signaling molecule-deficient B cells, we demonstrate that this activation is mediated by Lyn and Syk, Btk, phospholipase C-gamma2, and inositol-1,4,5-trisphosphate receptor-mediated Ca(2+) release. In addition, although Ral can be activated by Ras-independent mechanisms, we demonstrate that BCR-controlled activation of Ral is dependent on Ras. By means of expression of the dominant-negative mutants RasN17 and RalN28, or of RalBPDeltaGAP, a Ral effector mutant which sequesters active Ral, we show that Ras and Ral mediate BCR-controlled transcription of c-fos. Furthermore, while not involved in NF-kappaB activation, Ras and Ral mediate BCR-controlled activation of JUN/ATF2 and NFAT transcription factors. Taken together, our data show that Ral is activated upon BCR stimulation and mediates BCR-controlled activation of AP-1 and NFAT transcription factors. These findings suggest that Ral plays an important role in B cell development and function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237388     DOI: 10.4049/jimmunol.178.3.1405

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  NFAT, immunity and cancer: a transcription factor comes of age.

Authors:  Martin R Müller; Anjana Rao
Journal:  Nat Rev Immunol       Date:  2010-08-20       Impact factor: 53.106

Review 2.  BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Authors:  M Spaargaren; M F M de Rooij; A P Kater; E Eldering
Journal:  Oncogene       Date:  2014-06-23       Impact factor: 9.867

3.  Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2.

Authors:  Kayla A Martin; Matteo Cesaroni; Michael F Denny; Lena N Lupey; Italo Tempera
Journal:  Mol Cell Biol       Date:  2015-09-14       Impact factor: 4.272

4.  The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.

Authors:  Nicole F Neel; Timothy D Martin; Jeran K Stratford; Tanya P Zand; David J Reiner; Channing J Der
Journal:  Genes Cancer       Date:  2011-03

Review 5.  The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies.

Authors:  K H Shain; J Tao
Journal:  Oncogene       Date:  2013-09-16       Impact factor: 9.867

Review 6.  RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.

Authors:  Chao Yan; Dan Theodorescu
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

7.  Physical and functional characterization of the genetic locus of IBtk, an inhibitor of Bruton's tyrosine kinase: evidence for three protein isoforms of IBtk.

Authors:  Carmen Spatuzza; Marco Schiavone; Emanuela Di Salle; Elzbieta Janda; Marco Sardiello; Giuseppe Fiume; Olga Fierro; Marco Simonetta; Notis Argiriou; Raffaella Faraonio; Rosanna Capparelli; Ileana Quinto; Giuseppe Scala
Journal:  Nucleic Acids Res       Date:  2008-07-02       Impact factor: 16.971

Review 8.  Ral signaling pathway in health and cancer.

Authors:  Adel Rezaei Moghadam; Elham Patrad; Elham Tafsiri; Warner Peng; Benjamin Fangman; Timothy J Pluard; Anthony Accurso; Michael Salacz; Kushal Shah; Brandon Ricke; Danse Bi; Kyle Kimura; Leland Graves; Marzieh Khajoie Najad; Roya Dolatkhah; Zohreh Sanaat; Mina Yazdi; Naeimeh Tavakolinia; Mohammad Mazani; Mojtaba Amani; Saeid Ghavami; Robyn Gartell; Colleen Reilly; Zaid Naima; Tuba Esfandyari; Faris Farassati
Journal:  Cancer Med       Date:  2017-10-18       Impact factor: 4.452

9.  The transcription factor Gli3 promotes B cell development in fetal liver through repression of Shh.

Authors:  Anisha Solanki; Ching-In Lau; José Ignacio Saldaña; Susan Ross; Tessa Crompton
Journal:  J Exp Med       Date:  2017-05-22       Impact factor: 14.307

10.  Analysis of a wild mouse promoter variant reveals a novel role for FcγRIIb in the control of the germinal center and autoimmunity.

Authors:  Marion Espéli; Menna R Clatworthy; Susanne Bökers; Kate E Lawlor; Antony J Cutler; Frank Köntgen; Paul A Lyons; Kenneth G C Smith
Journal:  J Exp Med       Date:  2012-10-29       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.